5 completed, 4 recruiting, 2 terminated, 1 active not recruiting. 14 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 5, Recruiting 4, Terminated 2, Active not recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 5 | Recruiting 3, Completed 1, Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Visudyne: new trials by email Literature Review of Visudyne trials Research Report on Visudyne
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SCARFREE-001: Verteporfin for Scar Prevention Verteporfin Injection, Saline injection - Surgical Scar | Phase 2 | Recruiting | Odense University Hospital | 12 | 2026-10-01 | 2026-10-27 |
| Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System Photodynamic Therapy (PDT), Verteporfin Injection - Prostate Cancer | Phase 1 / Phase 2 | Recruiting | SpectraCure AB | 43 | 2025-01-06 | 2026-05-01 |
| Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer Biopsy, Biospecimen Collection, Computed Tomography - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 2 | Active not recruiting | Mayo Clinic | 24 | 2024-12-06 | 2026-06-18 |
| Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction Biospecimen Collection, Computed Tomography, Endobronchial Ultrasound Bronchoscopy - Malignant Solid Neoplasm | Phase 1 / Phase 2 | Recruiting | Roswell Park Cancer Institute | 42 | 2024-10-01 | 2026-04-06 |
| Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma Verteporfin - Glioblastoma, Recurrent Glioblastoma | Phase 1 / Phase 2 | Terminated | Emory University | 9 | 2021-01-15 | 2026-10-28 |
| Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study Endoscopic Ultrasound, Fluorescence Imaging, Photodynamic Therapy - Advanced Pancreatic Carcinoma, Locally Advanced Pancreatic Carcinoma | Phase 2 | Completed | Mayo Clinic | 13 | 2017-05-31 | 2025-07-30 |
| Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System Verteporfin, SpectraCure P18 System - Recurrent Prostate Cancer | Phase 1 / Phase 2 | Recruiting | SpectraCure AB | 66 | 2017-03-21 | 2026-05-01 |
| Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy Verteporfin, ranibizumab - Chronic Central Serous Chorioretinopathy | Phase 1 / Phase 2 | Completed | Jang Won Heo | 34 | 2009-07-01 | 2013-05-27 |
| Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis ranibizumab, verteporfin - Presumed Ocular Histoplasmosis (POHS) | Phase 2 | Unknown | Barnes Retina Institute | 30 | 2007-10-01 | 2009-04-16 |
| Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL) verteporfin, ranibizumab, dexamethasone - Choroidal Neovascularization, Macular Degeneration | Phase 2 | Completed | QLT Inc. | 162 | 2007-07-01 | 2011-06-02 |
| Ranibizumab and Reduced Fluence PDT for AMD ranibizumab, verteporfin - Macular Degeneration | Phase 2 | Completed | Texas Retina Associates | 60 | 2007-05-01 | 2025-11-28 |
| Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) Verteporfin Photodynamic Therapy, Ranibizumab, Placebo - Macular Degeneration, Choroidal Neovascularization | Phase 2 / Phase 3 | Terminated | Novartis | 255 | 2007-05-01 | 2011-04-21 |
| Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself Visudyne, Lucentis, Dexamethasone - Age Related Macular Degeneration | Phase 2 | Withdrawn | Vitreous -Retina- Macula Consultants of New York | 2007-01-01 | 2017-08-23 | |
| Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration Visudyne, Kenalog - Age-Related Macular Degeneration | Phase 2 | Completed | Manhattan Eye, Ear & Throat Hospital | 106 | 2003-10-01 | 2007-07-12 |
Macular Degeneration (5) · Choroidal Neovascularization (2) · Pancreatic Neoplasms (2) · Prostatic Neoplasms (2) · Cicatrix (1) · Glioblastoma (1) · Histoplasmosis (1) · Neovascularization, Pathologic (1) · Vision Disorders (1)
Mayo Clinic (2) · SpectraCure AB (2) · Barnes Retina Institute (1) · Emory University (1) · Jang Won Heo (1) · Manhattan Eye, Ear & Throat Hospital (1) · Novartis (1) · Odense University Hospital (1) · QLT Inc. (1) · Roswell Park Cancer Institute (1) · Texas Retina Associates (1) · Vitreous -Retina- Macula Consultants of New York (1)
United States (10) · Canada (3) · Denmark (2) · Germany (2) · United Kingdom (2) · Austria (1) · Belgium (1) · France (1) · Hungary (1) · Italy (1) · Netherlands (1) · Poland (1) · South Korea (1) · Spain (1) · Sweden (1)
Allen Ho, MD (1) · Andrew Strong, Ph.D (1) · David Callanan, MD (1) · David Hebbelstrup Jensen, MD, Ph.d. (1) · Henry Hudson, MD (1) · Jang Won Heo, Professor (1) · Jonathan Fainberg, MD, MPH (1) · Kevin J. Blinder, MD (1) · Nathaniel Ivanick (1) · Oscar Cuzzani, MD (1) · Richard F. Spaide, MD (1) · Vinay Chandrasekhara, M.D. (1) · Vinay Chandrasekhara, MD (1) · William L Read, MD (1)
PMID 21742303, PMID 22424834, PMID 23410808, PMID 25079064, PMID 33647286, PMID 34261044, PMID 40522203
P01CA084203 (2), 2025 (1), P30CA138292 (1), R01CA283547 (1)